Hudson Bay Capital Management
AIMT

Hudson Bay Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Hudson Bay Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,000
Closed -$992K – 577
2017
Q3 		$992K Buy
+40,000
New +$862K 0.02% 303

Hudson Bay Capital Management's AIMT Position: Q4 2020 in Review

Hudson Bay Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 116,700 shares — an estimated $4.02M sold.

Hudson Bay Capital Management first reported a position in AIMT in Q2 2017 and held it in 14 quarters. The position peaked at $11.2M in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Hudson Bay Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 116,700 Aimmune Therapeutics shares in Q4 2020, an estimated $4.02M.
  • Hudson Bay Capital Management first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 14 quarters.
  • Hudson Bay Capital Management's Aimmune Therapeutics position peaked at $11.2M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.